tbuckley/cabot-search huggingface dataset:
IVF Transfer of Fresh or Frozen Embryos in Women without Polycystic Ovaries
Authors: Lan N. Vuong, Vinh Q. Dang, Tuong M. Ho, Bao G. Huynh, Duc T. Ha, Toan D. Pham, Linh K. Nguyen, Robert J. Norman, Ben W. Mol
Journal: New England Journal of Medicine (2018)

Among women who are undergoing in vitro fertilization (IVF), the transfer of frozen embryos has been shown to result in a higher rate of live birth than the transfer of fresh embryos in those with infertility associated with the polycystic ovary syndrome. It is not known whether frozen-embryo transfer results in similar benefit in women with infertility that is not associated with the polycystic ovary syndrome.We randomly assigned 782 infertile women without the polycystic ovary syndrome who were undergoing a first or second IVF cycle to receive either a frozen embryo or a fresh embryo on day 3. In the frozen-embryo group, all grade 1 and 2 embryos had been cryopreserved, and a maximum of two embryos were thawed on the day of transfer in the following cycle. In the fresh-embryo group, a maximum of two fresh embryos were transferred in the stimulated cycle. The primary outcome was ongoing pregnancy after the first embryo transfer.After the first completed cycle, ongoing pregnancy occurred in 142 of 391 women (36.3%) in the frozen-embryo group and in 135 of 391 (34.5%) in the fresh-embryo group (risk ratio in the frozen-embryo group, 1.05; 95% confidence interval [CI], 0.87 to 1.27; P=0.65). Rates of live birth after the first transfer were 33.8% and 31.5%, respectively (risk ratio, 1.07; 95% CI, 0.88 to 1.31).Among infertile women without the polycystic ovary syndrome who were undergoing IVF, the transfer of frozen embryos did not result in significantly higher rates of ongoing pregnancy or live birth than the transfer of fresh embryos. (Funded by My Duc Hospital; ClinicalTrials.gov number, NCT02471573 .).
Autosomal Recessive Hypercholesterolemia
Authors: Laura D’Erasmo, Ilenia Minicocci, Antonio Nicolucci, Paolo Pintus, Janine E. Roeters Van Lennep, Luis Masana, Pedro Mata, Rosa Maria Sánchez-Hernández, Pablo Prieto-Matos, Josè T. Real, Juan F. Ascaso, Eduardo Esteve Lafuente, Miguel Pocovi, Francisco J. Fuentes, Sandro Muntoni, Stefano Bertolini, Cesare Sirtori, Laura Calabresi, Chiara Pavanello, Maurizio Averna, Angelo Baldassare Cefalu, Davide Noto, Adolfo Arturo Pacifico, Giovanni Mario Pes, Mariko Harada-Shiba, Enzo Manzato, Sabina Zambon, Alberto Zambon, Anja Vogt, Marco Scardapane, Barbara Sjouke, Renato Fellin, Marcello Arca
Journal: Journal of the American College of Cardiology (2018)
Reply to: “Reply to: ‘Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries’”
Authors: Ana da Silva Filipe, Vattipally Sreenu, Joseph Hughes, Elihu Aranday-Cortes, William L. Irving, Graham R. Foster, Kosh Agarwal, William Rosenberg, Douglas Macdonald, Paul Richardson, Mark A. Aldersley, Martin Wiselka, Andrew Ustianowski, John McLauchlan, Emma C. Thomson
Journal: Journal of Hepatology (2018)
Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy
Authors: F. Stephen Hodi, Marcus Ballinger, Benjamin Lyons, Jean-Charles Soria, Mizuki Nishino, Josep Tabernero, Thomas Powles, David Smith, Axel Hoos, Chris McKenna, Ulrich Beyer, Ina Rhee, Gregg Fine, Nathan Winslow, Daniel S. Chen, Jedd D. Wolchok
Journal: Journal of Clinical Oncology (2018)

Purpose Treating solid tumors with cancer immunotherapy (CIT) can result in unconventional responses and overall survival (OS) benefits that are not adequately captured by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1. We describe immune-modified RECIST (imRECIST) criteria, designed to better capture CIT responses. Patients and Methods Atezolizumab data from clinical trials in non–small-cell lung cancer, metastatic urothelial carcinoma, renal cell carcinoma, and melanoma were evaluated. Modifications to imRECIST versus RECIST v1.1 included allowance for best overall response after progressive disease (PD) and changes in PD definitions per new lesions (NLs) and nontarget lesions. imRECIST progression-free survival (PFS) did not count initial PD as an event if the subsequent scan showed disease control. OS was evaluated using conditional landmarks in patients whose PFS differed by imRECIST versus RECIST v1.1. Results The best overall response was 1% to 2% greater, the disease control rate was 8% to 13% greater, and the median PFS was 0.5 to 1.5 months longer per imRECIST versus RECIST v1.1. Extension of imRECIST PFS versus RECIST v1.1 PFS was associated with longer or similar OS. Patterns of progression analysis revealed that patients who developed NLs without target lesion (TL) progression had a similar or shorter OS compared with patients with RECIST v1.1 TL progression. Patients infrequently experienced a spike pattern (TLs increase, then decrease) but had longer OS than patients without TL reversion. Conclusion Evaluation of PFS and patterns of response and progression revealed that allowance for TL reversion from PD per imRECIST may better identify patients with OS benefit. Progression defined by the isolated appearance of NLs, however, is not associated with longer OS. These results may inform additional modifications to radiographic criteria (including imRECIST) to better reflect efficacy with CIT agents.
Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline
Authors: Hedy L. Kindler, Nofisat Ismaila, Samuel G. Armato, Raphael Bueno, Mary Hesdorffer, Thierry Jahan, Clyde Michael Jones, Markku Miettinen, Harvey Pass, Andreas Rimner, Valerie Rusch, Daniel Sterman, Anish Thomas, Raffit Hassan
Journal: Journal of Clinical Oncology (2018)

Purpose To provide evidence-based recommendations to practicing physicians and others on the management of malignant pleural mesothelioma. Methods ASCO convened an Expert Panel of medical oncology, thoracic surgery, radiation oncology, pulmonary, pathology, imaging, and advocacy experts to conduct a literature search, which included systematic reviews, meta-analyses, randomized controlled trials, and prospective and retrospective comparative observational studies published from 1990 through 2017. Outcomes of interest included survival, disease-free or recurrence-free survival, and quality of life. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations. Results The literature search identified 222 relevant studies to inform the evidence base for this guideline. Recommendations Evidence-based recommendations were developed for diagnosis, staging, chemotherapy, surgical cytoreduction, radiation therapy, and multimodality therapy in patients with malignant pleural mesothelioma. Additional information is available at www.asco.org/thoracic-cancer-guidelines and www.asco.org/guidelineswiki .
Psychotic symptoms in people with intellectual disability
Authors: Giri P Madhavan
Journal: BMJ (2018)

I commend Sami and colleagues for the topic and scope of their article on psychotic symptoms in non-specialist settings, which is well suited to a broad audience.1 Compressing such a large amount of information into a concise Practice Pointer inevitably results in omissions, and, in this case, the opportunity was missed to inform non-specialist readers …
Sixty seconds on . . . marijuana smoke
Authors: Anne Gulland
Journal: BMJ (2018)

Very funny. An editorial in JAMA Internal Medicine 1 agrees and calls for the dangers of secondhand exposure to marijuana smoke to be taken as seriously as the dangers of secondhand tobacco smoke. It says that smoking cannabis is socially acceptable and is often viewed as benign, or even good for you because of its therapeutic use, so people ignore its potential harms.

Are you going to carry …
Eosinophilic esophagitis during milk oral immunotherapy: a growing concern
Authors: Bruna Pultrini Aquilante, Maria Carolina Nhola Faion, Fernanda Marcelino Silva Veiga, Gustavo Soldateli, Glauce Hiromi Yonamine, Cristiane N. Santos, Mayra B. Dorna, Antonio C. Pastorino, Ana Paula C. Moschione
Journal: Journal of Allergy and Clinical Immunology (2018)
Abstract 18146: Targeted Temperature Management After Cardiac Arrest: The Montreal Heart Institute experience
Authors: Nadia Boule-Laghzali, Laura Dominguez Perez, Jean-François Tanguay, Katia Dyrda, Malorie Chabot-Blanchet, Yoan Lamarche, Daniel Parent, Anne-Frédérique Dupriez, Alain Deschamps, Anique Ducharme
Journal: Circulation (2016)

Introduction: TTM improves neurological function and survival in patients with cardiac arrest and an initially shockable rhythm. However, many centers do not restrict TTM to VF/VT patients as recen...
Normal karyotype in myelofibrosis: is prognostic integrity affected by the number of metaphases analyzed?
Authors: Maura Nicolosi, Mythri Mudireddy, Naseema Gangat, Animesh Pardanani, Curtis A. Hanson, Rhett P. Ketterling, Ayalew Tefferi
Journal: Blood Cancer Journal (2018)

Primary myelofibrosis (PMF) is a clonal myeloproliferative neoplasm (MPN) characterized by anemia, marked splenomegaly, extramedullary hematopoiesis, profound constitutional symptoms, and a propensity to progress into acute leukemia, resulting in premature death 1 .These features in PMF are accompanied by three mutually exclusive driver mutations: JAK2, CALR, and MPL 2, 3 .Current prognostic systems in PMF are mostly based on clinical parameters, with the exception of the dynamic international prognostic system (DIPSS)-plus, which includes cytogenetic information 4 .DIPSS-plus classifies karyotype in PMF as being either "favorable" or "unfavorable".The former includes normal karyotype or sole abnormalities of trisomy 9, del(13q), del(20q), translocation/duplication of chromosome 1 and loss of Y chromosome, while the latter includes all other abnormalities 5 .It is currently unknown whether or not the prognostic integrity of "normal" karyotype in PMF is affected by the number of metaphases examined, or the presence of single-metaphase abnormalities classically associated with myeloid disorders that do not otherwise meet the International System for Human Cytogenetic Nomenclature (ISCN) criteria for constituting "clonal" changes 6 .The current study addresses these issues in a consecutive series of 604 patients with PMF and "normal" karyotype.
The Edinburgh CT and genetic diagnostic criteria for lobar intracerebral haemorrhage associated with cerebral amyloid angiopathy: model development and diagnostic test accuracy study
Authors: Mark A Rodrigues, Neshika Samarasekera, Christine Lerpiniere, Catherine Humphreys, Mark O McCarron, Philip M White, James A R Nicoll, Cathie L M Sudlow, Charlotte Cordonnier, Joanna M Wardlaw, Colin Smith, Rustam Al-Shahi Salman
Journal: The Lancet Neurology (2018)

Identification of lobar spontaneous intracerebral haemorrhage associated with cerebral amyloid angiopathy (CAA) is important because it is associated with a higher risk of recurrent intracerebral haemorrhage than arteriolosclerosis-associated intracerebral haemorrhage. We aimed to develop a prediction model for the identification of CAA-associated lobar intracerebral haemorrhage using CT features and genotype.
Predicting Peanut Allergy in an Unbiased Allergy Clinic Population Using Peanut Specific IgE Levels Measured in Two Independent Assays: Immunocap and Immulite 2000
Authors: Carah B. Santos, Bruce J. Lanser, Matthew J. Strand, Erwin W. Gelfand
Journal: Journal of Allergy and Clinical Immunology (2018)
Evidence of low incidence of myelodysplastic syndrome (MDS) in patients exposed to bendamustine treatment for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Authors: John M. Burke, Kristen Bibeau, Brad Kahl, Kenneth R. Carson, Andrew D. Zelenetz, Danielle M. Brander, Kami J. Maddocks, John F. Gerecitano, Ashutosh K. Pathak, Bruce D. Cheson
Journal: Journal of Clinical Oncology (2017)

e19008 Background: CLL/SLL is a treatable malignancy, which is responsive to therapies that include bendamustine. However, as with many alkylating agents, there is concern for the development of secondary malignancies and MDS after exposure to bendamustine. We evaluated the risk of MDS using electronic medical records from a geographically diverse cohort of cancer patients (pts). Methods: Pathologically confirmedCLL/SLL pts with any exposure to bendamustine were identified in the Flatiron Health database (FHD, Flatiron Health, New York [122016]). This is a longitudinal US-based cohort with &gt; 1.5 million cancer pts drawn from over 250 cancer clinics. Pts with bendamustine exposure and no history of MDS or other malignancy were included. Pts were followed longitudinally to identify incident cases of secondary malignancies or MDS. Results: Of 3140 CLL/SLL pts in the analytic cohort, 1022 met inclusion criteria. Median follow-up after bendamustine exposure was 1.7 years. Overall, 8% received bendamustine monotherapy, 84% received combination therapy, and 8% received cycles of bendamustine monotherapy and combination therapy. Of the 1022 pts, 205 (20%) had prior antineoplastic exposure, a risk factor for MDS. During the follow-up period, five pts developed MDS (0.48% of the bendamustine-exposed cohort), one of whom had prior antineoplastic exposure. Conclusions: This real-world study demonstrated that pts received bendamustine overwhelmingly as combination therapy, and 20% had prior antineoplastic exposure. MDS related to alkylators and purine analogs can have a latency of &gt; 3 years; in this study a minority (~20%) of pts had &gt; 3 years of follow-up. Thus, longer follow-up is required to draw definitive conclusions regarding the risk. Nevertheless, the FHD provides a source of oncology data for studying long-term outcomes of cancer pts, which have historically been difficult to capture in epidemiological studies. At a median of 1.7 years after exposure, the current study identified a low risk of MDS after controlling for potential confounders.
Progression in the <i>LRRK2</i>-Associated Parkinson Disease Population
Authors: Rachel Saunders-Pullman, Anat Mirelman, Roy N. Alcalay, Cuiling Wang, Roberto A. Ortega, Deborah Raymond, Helen Mejia-Santana, Martha Orbe-Reilly, Brooke A. Johannes, Avner Thaler, Laurie Ozelius, Avi Orr-Urtreger, Karen S. Marder, Nir Giladi, Susan B. Bressman
Journal: JAMA Neurology (2018)

Few prospective longitudinal studies have evaluated the progression of Parkinson disease (PD) in patients with the leucine-rich repeat kinase 2 (LRRK2 [OMIM 609007]) mutation. Knowledge about such progression will aid clinical trials.To determine whether the longitudinal course of PD in patients with the LRRK2 mutation differs from the longitudinal course of PD in patients without the mutation.A prospective comprehensive assessment of a large cohort of patients from 3 sites with LRRK2 PD or with nonmutation PD was conducted from July 21, 2009, to September 30, 2016. All patients of Ashkenazi Jewish ancestry with PD were approached at each site; approximately 80% agreed to an initial visit. A total of 545 patients of Ashkenazi Jewish descent with PD who had 1 to 4 study visits were evaluated. A total of 144 patients (26.4%) had the LRRK2 G2019S mutation. Patients with GBA (OMIM 606463) mutations were excluded from the analysis.Linear mixed-effects models for longitudinal motor scores were used to examine the association of LRRK2 mutation status with the rate of change in Unified Parkinson's Disease Rating Scale III scores using disease duration as the time scale, adjusting for sex, site, age, disease duration, cognitive score, and levodopa-equivalent dose at baseline. Mixed-effects models were used to assess change in cognition, as measured by Montreal Cognitive Assessment scores.Among the 545 participants, 233 were women, 312 were men, and the mean (SD) age was 68.2 (9.1) years for participants with the LRRK2 mutation and 67.8 (10.7) years for those without it. Seventy-two of 144 participants with the LRRK2 mutation and 161 of 401 participants with no mutation were women. The estimate (SE) of the rate of change in the Unified Parkinson's Disease Rating Scale III motor score per year among those with the LRRK2 mutation (0.689 [0.192] points per year) was less than among those without the mutation (1.056 [0.187] points per year; difference, -0.367 [0.149] points per year; P = .02). The estimate (SE) of the difference in the rate of change of the Montreal Cognitive Assessment score between those with the LRRK2 mutation (-0.096 [0.090] points per year) and those without the mutation (-0.192 [0.102] points per year) did not reach statistical significance (difference, 0.097 [0.055] points per year; P = .08).Prospective longitudinal follow-up of patients with PD with or without the LRRK2 G2019S mutation supports data from a cross-sectional study and demonstrates a slower decline in motor Unified Parkinson's Disease Rating Scale scores among those with LRRK2 G2019S-associated PD.
Co-delivery of tumor antigen and dual toll-like receptor ligands into dendritic cell by silicon microparticle enables efficient immunotherapy against melanoma
Authors: Motao Zhu, Xilai Ding, Ruifang Zhao, Xuewu Liu, Haifa Shen, Chunmei Cai, Mauro Ferrari, Helen Y. Wang, Rong-Fu Wang
Journal: Journal of Controlled Release (2018)
Carfilzomib-Based Combination Regimens Are Highly Effective Frontline Therapies for Multiple Myeloma and Waldenström's Macroglobulinemia
Authors: Maria Chaudhry, Raphael Steiner, Catherine M. Claussen, Krina Patel, Hans C. Lee, Donna M. Weber, Sheeba K. Thomas, Chun Feng, Mark Kramer, Behrang Amini, Robert Z. Orlowski, Lei Feng, Elisabet E. Manasanch
Journal: Blood (2017)
Incorporating Radiation Oncology into Immunotherapy: proceedings from the ASTRO-SITC-NCI immunotherapy workshop
Authors: Ariel E. Marciscano, Joshua M. Walker, Heather M. McGee, Michelle M. Kim, Charles A. Kunos, Arta M. Monjazeb, Stephen L. Shiao, Phuoc T. Tran, Mansoor M. Ahmed
Journal: Journal for ImmunoTherapy of Cancer (2018)

Radiotherapy (RT) has been a fundamental component of the anti-cancer armamentarium for over a century. Approximately half of all cancer patients are treated with radiotherapy during their disease course. Over the two past decades, there has been a growing body of preclinical evidence supporting the immunomodulatory effects of radiotherapy, particularly when combined with immunotherapy, but only anecdotal clinical examples existed until recently. The renaissance of immunotherapy and the recent U.S. Food and Drug Administration (FDA) approval of several immune checkpoint inhibitors (ICIs) and other immuno-oncology (IO) agents in multiple cancers provides the opportunity to investigate how localized radiotherapy can induce systemic immune responses. Early clinical experiences have demonstrated feasibility of this approach but additional preclinical and clinical investigation is needed to understand how RT and immunotherapy can be optimally combined.To address questions that are critical to successful incorporation of radiation oncology into immunotherapy, the American Society for Radiation Oncology (ASTRO), the Society for Immunotherapy of Cancer (SITC) and the National Cancer Institute (NCI) organized a collaborative scientific workshop, Incorporating Radiation Oncology into Immunotherapy, that convened on June 15 and 16 of 2017 at the Natcher Building, NIH Campus in Bethesda, Maryland. This report summarizes key data and highlights from each session.
Iris pigmented lesions as a marker of cutaneous melanoma risk: an Australian case-control study
Authors: A.M. Laino, E.G. Berry, K. Jagirdar, K.J. Lee, D.L. Duffy, H.P. Soyer, R.A. Sturm
Journal: British Journal of Dermatology (2018)

Iris naevi and iris freckles have a frequency of 4% and 50% in the European population, respectively. They are associated with dysplastic naevi, but few studies have examined their link to cutaneous melanoma. To assess whether iris pigmented lesions are a predictive indicator for cutaneous melanoma. This is a melanoma case–control study of 1254 European‐background Australians. Sun exposure and melanoma history, a saliva sample for DNA analysis and eye photographs taken with a digital camera were collected from 1117 participants. Iris images were assessed by up to four trained observers for the number of iris pigmented lesions. The data were analysed for correlations between iris pigmented lesions and melanoma history. Case participants over the age of 40 had similar numbers of iris pigmented lesions to age matched controls (mean 5·7 vs. 5·2, P = 0·02), but in younger case and control participants there was a greater difference (mean 3·96 vs. 2·19, P = 0·004). A logistic regression adjusted for age, sex, skin, hair and eye colour, skin freckling and naevus count found that the presence of three or more iris pigmented lesions increases the melanoma risk 1·45‐fold [95% confidence interval (CI) 1·07–1·95]. HERC2/OCA2 rs12913832 and IRF4 rs12203592 influenced both eye colour and the number of iris pigmented lesions. On the HERC2/OCA2 A/A and A/G genotype background there was an increasing proportion of blue eye colour when carrying the IRF4 T allele (P = 3 × 10−4) and a higher number of iris pigmented lesions with the IRF4 T/T homozygote (P = 3 × 10−9). Iris pigmented lesion count provides additional predictive information for melanoma risk above that from conventional risk factors.